Share
Kyverna Therapeutics’ KYV-101 is a new, fully human anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Credit: Meletios Verras via Shutterstock.com.

Kyverna Therapeutics has enrolled the first participant in its Phase I clinical trial of KYV-101 to treat lupus nephritis (LN) in the US.

The dose escalation, open-label, multi-centre Phase I clinical trial has been designed for evaluating KYV-101’s safety in refractory LN patients.

Related Company Profiles

View all

Approximately nine to 12 LN patients across the US are expected to be enrolled in the trial.

A new, fully human anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, KYV-101 has been designed for use in B cell-driven autoimmune diseases, such as LN.

It specifically targets CD19, which is a protein that is expressed on the B cell’s surface.

B cells are involved in many types of malignancies, including autoimmune diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company expects that its investigational CAR T-cell therapy may offer new hope for those patients who have exhausted tapping the conventional treatment options.

Kyverna Therapeutics CEO Peter Maag said: “We are immensely proud to have reached this significant milestone in our journey to transform the lives of patients battling life-altering ailments such as LN.

“Our KYV-101 cell therapy has the potential to revolutionise treatment for individuals suffering from autoimmune diseases, with patients currently being treated for multiple indications across the US and Europe.

“We look forward to advancing our clinical programmes so we can bring a new option to patients as quickly as possible.”

In November last year, the company received clearance for its investigational new drug (IND) application from the US Food and Drug Administration (FDA) to start the Phase I clinical trial of KYV-101 for LN treatment.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.